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There are several reasons to consider the role of endothelial cells in COVID-19 and other
emerging viral infections. First, severe cases of COVID-19 show a common breakdown
of central vascular functions. Second, SARS-CoV-2 replicates in endothelial cells. Third,
prior deterioration of vascular function exacerbates disease, as the most common
comorbidities of COVID-19 (obesity, hypertension, and diabetes) are all associated
with endothelial dysfunction. Importantly, SARS-CoV-2’s ability to infect endothelium
is shared by many emerging viruses, including henipaviruses, hantavirus, and highly
pathogenic avian influenza virus, all specifically targeting endothelial cells. The ability
to infect endothelium appears to support generalised dissemination of infection and
facilitate the access to certain tissues. The disturbed vascular function observed in
severe COVID-19 is also a prominent feature of many other life-threatening viral diseases,
underscoring the need to understand how viruses modulate endothelial function. We
here review the role of vascular endothelial cells in emerging viral infections, starting with
a summary of endothelial cells as key mediators and regulators of vascular and immune
responses in health and infection. Next, we discuss endotheliotropism as a possible
virulence factor and detail features that regulate viruses’ ability to attach to and enter
endothelial cells. We move on to review how endothelial cells detect invading viruses
and respond to infection, with particular focus on pathways that may influence vascular
function and the host immune system. Finally, we discuss how endothelial cell function
can be dysregulated in viral disease, either by viral components or as bystander victims
of overshooting or detrimental inflammatory and immune responses. Many aspects of
how viruses interact with the endothelium remain poorly understood. Considering the
diversity of such mechanisms among different emerging viruses allows us to highlight
common features that may be of general validity and point out important challenges.
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INTRODUCTION
As the human population expands, a closer proximity to wild animals and their habitat has resulted
in a more frequent spillover of viral infections to humans and livestock. At the same time, our
mobility has increased. This augments the risk that emerging infections can spread globally. As
a result, evolving infections pose a significant threat to human and animal health and the global
economy. This is clearly illustrated by the ongoing severe acute respiratory syndrome coronavirus
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2 (SARS-CoV-2) pandemic (>2.1 million deaths). Other recent
epidemics include the 2014-2016 Ebola outbreak in West Africa
(>11,000 deaths), the MERS-CoV outbreak in Saudi Arabia
2012-2019 (>850 deaths), and regular outbreaks of highly fatal
Nipah virus infection in Bangladesh and surrounding countries,
among others (1).
A characteristic feature of SARS-CoV-2 is that the virus,
in addition to infecting airway epithelial cells, also infects
endothelial cells (2–4). This infection pattern can be recapitulated
in the laboratory, as SARS-CoV-2 infects and replicates in human
capillary organoids (5). However, it is not known if replication
in endothelial cells is a ubiquitous feature of disease or limited
to certain patient groups or clinical presentations. Coronavirus
disease 2019 (COVID-19) has an increased case fatality rate in
individuals suffering from conditions associated with endothelial
dysfunction (diabetes, hypertension, and cardiovascular disease)
(6). Furthermore, typical clinical signs in severe COVID-19 are
compatible with breakdown of vascular function (multi-organ
endothelial damage, thrombosis and angiopathies, dysregulated
inflammation, and pulmonary oedema) (2, 3, 7). To this end, it is
highly relevant to address the role of the vascular compartment
in COVID-19 (7, 8).
SARS-CoV-2’s ability to infect endothelial cells is shared
by many emerging viruses with great relevance to human
and animal health. For example, henipavirus infection leads
to widespread infection of endothelial and vascular smooth
muscle cells, with extensive vasculitis and occasional endothelial
syncytia formation (9, 10). In hantavirus pulmonary syndrome,
there is severe dysregulation of vascular permeability and strong
expression of viral antigens in the pulmonary microvasculature
(11). Substantial endothelial expression of viral antigens is
also observed in several emerging infections of animals, which
have a major impact on animal welfare and sustainable food
production. Highly pathogenic avian influenza virus (HPAIV,
also relevant because of its zoonotic potential) (12) and
pathogenic variants of infectious salmon anaemia virus (ISAV)
(13) are prime examples of viruses that infect endothelial
cells of production animals. Other viruses have a more
generalised cell tropism, but show some degree of endothelial
infection during natural infection. Relevant examples include
the flaviviruses (such as dengue virus) (14) and filoviruses
(Ebola and Marburg viruses) (15). Table 1 provides a list of
viral pathogens discussed in the current article and associated
pathological findings of vascular disease. However, the complete
list of all viruses that target the endothelium would be much
more extensive.
In addition, severe viral disease more often than not
includes signs related to dysregulated vascular function. Typical
presentations include dysregulated blood flow, uncontrolled
inflammation and vascular permeability, and microvascular
thrombosis and bleeding. Importantly, vascular function may
also be disturbed in the absence of endothelial infection. This
can result from signalling from infected cells or collateral damage
when immune cells attempt to limit infection. In conclusion, the
question of how viruses target the endothelium, either directly or
as bystanders, appears central to understand the pathogenesis of
disseminated viral disease.
Complementary to several recent reviews that discuss the
vascular component of COVID-19 [e.g., (8, 18, 19)], we here
broaden our perspective to consider the diversity by which
emerging viruses interact with endothelial cells. Briefly, we
review features of endothelial cells relevant to their role in the
pathogenesis of viral disease, summarise what is known about
viral properties that regulate their ability to infect endothelial
cells, and discuss how such tropism may affect the course of
infection and disease development. Our aim is not to provide
a complete overview of all viral interactions with endothelium,
but rather to provide examples that illustrate the range of
such interactions, highlight general principles, and point to
unanswered questions related to disease development.
ENDOTHELIAL FUNCTION IN
HOMEOSTASIS AND INFLAMMATION
Endothelial Cells Are Gatekeepers of the
Blood-Tissue Barrier
Endothelial cells line the inner surface of all blood and lymphatic
vessels. This single cell layer, the endothelium, creates a semi-
permeable barrier between blood or lymph and its surrounding
tissues. In an adult human, the vasculature contains ∼6 x 1011
endothelial cells (20), covering a surface area of 4,000–7,000 m2.
The vascular network is a highly branched closed circulation
that extends into all organs, nourishes every tissue, and provides
a gateway for extravasation of fluids, solutes, macromolecules,
hormones, and immune cells. Consequently, all possible entry
ports of viral infection are in close contact with endothelial cells.
A good example is the lower respiratory tract, where intimate
apposition between alveolar epithelial and lung microvascular
endothelial cells is required for efficient alveolar gas exchange.
Microvascular beds, composed of arterioles, capillaries, and post-
capillary venules, make up the greatest surface of the vascular
circulation by far and is where most physiological processes
brought on by the endothelium occur (21). This is also where
most virus-induced vascular pathology manifests.
Endothelial Profiles Vary Between Vascular
Beds, Branches, and Activation States
Endothelial cells show tissue- and vascular bed-specific profiles
that are likely to regulate their susceptibility and permissibility
to viral infection (22). For example, the observation of dengue
antigens in liver sinusoids (14) during natural infection should
be considered in light of the dengue virus’ ability to exploit
scavenger receptors for internalisation (23, 24). The vast
diversity among endothelial cells arises through a combination
of inputs that impose phenotypes of variable durability (25).
Some phenotypes are mitotically stable, like the epigenetic
modifications that define arterial and venous cells (26, 27). Others
provide memories of past stimulations, like biologically active
proteins with long half-lives stored in Weibel-Palade bodies (28).
Finally, endothelial phenotypes may also be highly dynamic, like
tip-stalk cell phenotypes in angiogenic sprouting (29). Similar to
many aspects of endothelial heterogeneity, the ability to regulate
critical vascular functions is dynamic and arises from cues within
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TABLE 1 | Viruses that infect endothelial cells and related vascular pathological findings.
Virus (Family) EC infection Vascular pathological features References
SARS-CoV-2 (coronaviridae) One of several cell types
infected
Intra-endothelial virus particles in all examined tissues; Multi-organ vascular
involvement; Endotheliitis with perivascular T cell and mononuclear cell infiltrates;
Severe endothelial injury with disrupted cell membranes, and apoptotic bodies;
Widespread thrombosis, congestion, and microangiopathy; Dysregulated
inflammation
(2–4)
Nipah and Hendra henipavirus
(paramyxoviridae)
Major cell type infected Widespread expression of viral antigens in endothelial and vascular smooth
muscle cells; Multi-organ vascular involvement; Endotheliitis affecting small
arteries, arterioles, capillaries, and venules; Focal neutrophil and mononuclear
infiltrates; Severe endothelial injury with segmented destruction, mural necrosis,
and fragmented nuclei; Necrosis and haemorrhages adjacent to damaged
endothelium; Endothelial syncytia, multinucleated giant cells
(9, 10)
Hantavirus (hantaviridae) Major cell type infected Viral antigens, viral inclusions bodies, and virus particles in pulmonary capillary
and small vessel endothelium; Less frequent presence of endothelial viral antigens
in extra-pulmonary tissues, with kidney being the most affected location;
Pulmonary and generalised vascular congestion, but histopathological changes
confined to lungs; Alveolar and interstitial oedema; Mononuclear cell infiltrates
without visible endotheliitis; Occasional swollen or enlarged endothelial cells, but
no evidence of necrosis or microvascular thrombosis
(11)
Influenza A, H5N1, H7N1
(orthomyxoviridae)
Major cell type infected Viral antigens in blood and lymphatic endothelial cells of all examined tissues; Viral
particles budding from the luminal side; Microvascular thrombosis; Multi-organ
vascular involvement with widespread necrotic and haemorrhagic foci and
oedema; Inflammation, except in per-acute disease
Infectious salmon anaemia
virus (orthomyxoviridae)
Major cell type infected Viral antigens and virus particles in endothelial cells of the primary and secondary
vascular system; Multi-organ vascular involvement, including bleeding,
congestion, and oedema; Severe anaemia; Absence of perivascular leukocyte
infiltrates
Ebolavirus (filoviridae) One of many cell types
infected
Endothelial infection becomes evident after onset of symptoms; Intra-endothelial
viral inclusion bodies and virus particles; Absence of inflammation and
morphological evidence of EC damage; Petechiae and ecchymoses on skin and
mucous membranes, internal haemorrhages, fibrin deposition suggestive of
consumptive coagulopathy; Multi-organ necrotic foci
(15, 16)
Dengue virus (flaviviridae) One of many cell types
infected
Viral antigens in endothelial cells of lung, liver, and heart; Diffuse haemorrhage,
oedema, and focal necrosis; Mononuclear cell infiltrates
(14, 17)
Zikavirus, West Nile virus
(flaviviridae)
Limited evidence of in vivo
endothelial infection
the extracellular environment (28, 30). Thus, maintaining blood
fluidity, regulating blood flow, controlling trans-endothelial
extravasation of plasma proteins, and controlling leukocyte
trafficking all respond to signals generated during homeostasis,
hypoxia, inflammation, and repair. Importantly, endothelial cells
may reside in a resting phenotype over long periods of time and
still maintain the ability to orchestrate dramatic responses when
activated (31).
Endothelial Cells Are Central Regulators of
Vascular Function
Endothelial cells control vascular functions, and tissue damage or
infection stimulates an endothelial phenotype that supports the
protective host response. However, overwhelming or persistant
activation can lead to endothelial dysfunction and contribute to
pathology (Figure 1).
Regulation of Blood Flow
Arterial endothelium plays an essential role in regulating blood
flow by controlling perivascular smooth muscle cell contraction.
The specific blood-flow mediators released by endothelial cells
vary in time and space, but the principal vaso-relaxant is
nitric oxide (NO) (32). NO is also linked to various other
endothelial functions, and reduced NO bioavailability is a central
feature of endothelial dysfunction (33). Indeed, a non-invasive
test for measuring the NO-mediated response to alterations in
blood pressure (brachial artery flow-mediated dilation, FMD)
is commonly used to define endothelial dysfunction (34). In a
recent position paper by the European Society for Cardiology,
FMD was proposed as a potential tool for risk stratification
in COVID-19 (7). The renin-angiotensin system is also a
key player in the regulation of blood pressure and organ
perfusion. Excessive activation of the renin-angiotensin system
by angiotensin II (ANG-II) causes vasoconstriction, as well as
vascular and cardiac damage. However, its counterregulation
by the angiotensin converting enzyme 2 (ACE2), the surface
protein used by SARS-CoV-2 for cellular attachment (35–37),
and its products, angiotensin 1-7 and angiotensin 1-9, balances
signalling to promote the perfusion of central organs like heart
and kidney (38).
Maintenance of Blood Fluidity
Under homeostatic conditions, the endothelium actively inhibits
coagulation (32). Because microvascular thrombosis is a clinical
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FIGURE 1 | Endothelial function in homeostasis and viral infection. (A,B) In homeostasis, endothelial cells promote a non-adherent vascular surface that promotes
tissue perfusion, limits inflammation and the transvascular movement of cells and proteins, and prevents clotting. (A,C) Upon viral infection or tissue damage,
endothelial cells are activated directly by viral components or indirectly by soluble mediators (IL-1, TNF, IL-6, IFNa, IFNb). Such activation initiates signalling that
culminates in activation and nuclear translocation of IRF and NF-kB transcription factors. This results in expression of interferon-stimulated genes (ISGs) and
inflammatory mediators (e.g., tissue factor, selectins, chemokines, and adhesion molecules) that promote antiviral responses, clotting, vascular permeability, and
leukocyte recruitment. In addition, type I activation of endothelial cells, for example by thrombin, causes a rapid release of pre-synthesised molecules (e.g., VWF,
ANGPT2, P-selectin, and CXCL8) with similar effects. (A,D) In the case of overwhelming or persistent activation, endothelial cells may become dysfunctional, resulting
in loss of control of vascular tone, permeability, and coagulation. In addition, direct viral damage to the endothelium further disrupts the vascular barrier and exposes
pro-thrombotic factors (tissue factor, collagen) that exacerbate dysfunctional coagulation.
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feature of many viral infections and central to COVID-19
(39), we here provide a brief overview of the mechanisms
involved. First, endothelial cells bind and present tissue factor
pathway inhibitors that block the action of the factor-VIIa-
tissue-factor complex (32). Second, endothelial cells produce
and display heparan sulphate proteoglycans in the glycocalyx
that bind anti-thrombin III, enabling inhibition of thrombin
molecules generated by the coagulation cascade (32). Third,
endothelial cells synthesise and present thrombomodulin, a cell
surface-bound protein that prevents thrombin from cleaving
fibrinogen, a key step in blood clot formation. Furthermore, this
thrombomodulin-bound thrombin efficiently activates protein
C, generating an enzyme that destroys certain clotting factors,
also inhibiting coagulation (32). Fourth, thrombin inactivation
by endothelial cells prevents platelet activation, another critical
element in maintaining blood fluidity. Endothelial cells also
produce and sequester von Willebrand factor (VWF) in
Weibel-palade bodies. VWF is a large multimeric glycoprotein
that plays a central role in coagulation, among others by
strengthening the binding between platelets and collagen in
the basement membrane (32). Finally, endothelial-produced
NO, prostacyclin, and prostaglandin E2 synergistically inhibit
platelet adhesion and aggregation (32). Importantly, in response
to pro-inflammatory activation, endothelial cells change from
an anti-coagulant to a pro-coagulant phenotype (Figure 1C).
Increased tissue factor expression and exposure of extracellular
matrix components like collagen initiate the extrinsic coagulation
cascade activation and increased production of thrombin and
fibrin. The resulting pro-thrombotic state is further exaggerated
by an elevation of plasminogen activator inhibitor 1 (PAI-I) that
suppresses the fibrinolytic system (40). Finally, secretion of VWF
promotes platelet activation and additional propagation of the
coagulation cascade.
Control of Vascular Permeability
Microvascular endothelial cells also regulate the extravasation of
fluids, solutes, and plasma proteins. Accordingly, dysregulation
of microvascular function mediates oedema and bleeding in viral
disease (41). The maintenance of microvascular integrity relies
on crosstalk between two key components of the endothelium,
the glycocalyx and the intercellular junctions. First, the luminal
surface of all vascular endothelial cells is covered by the
glycocalyx. This is a thick hydrated layer of glycoproteins with
acidic oligosaccharides and terminal sialic acids that confer a
net negative charge (42). Of note, these highly abundant sialic
acids are frequently exploited by viruses to attach to the cellular
surface (43). The glycocalyx also contains membrane-bound
proteoglycans with associated glycosaminoglycans like heparan
sulphates (42). It forms a gel-like interface between the plasma
membrane and the blood that is central to maintaining proper
barrier function, and its disruption leads to vascular leakage
(42, 44). Second, the conformation of endothelial intercellular
junctions is highly dynamic and responds to a range of stimuli
(45). Tight junction molecules regulate paracellular permeability
to ions and small molecules, and are therefore most prominent
at sites where strict regulation of vascular permeability is
essential, like the blood-brain barrier (46). In contrast, adherens
junction molecules are evenly distributed along the vascular
tree, and mediate permeability to large molecular weight plasma
components (46). Adherens junctions are also hubs for the
integration of cell-cell adhesion, cytoskeletal reorganisation, and
intracellular signalling (45). The highly endothelial cell-specific
vascular endothelial (VE)-cadherin (47) is a central component
of adherens junctions and has a crucial role in regulating the
permeability to plasma proteins across intact endothelium (48).
Orchestration of Leukocyte Recruitment
Venular endothelial cells keep tight control of leukocyte
trafficking from blood to tissues and orchestrate local
inflammatory responses, for example in viral pneumonia.
For leukocytes to cross the vessel wall, they must first adhere
to the endothelial surface. This process takes place in post-
capillary venules of inflamed tissues and has been entitled
the multistep adhesion cascade (49). Briefly, the capture and
rolling of leukocytes on endothelial surfaces is mediated by
P-, E-, and L-selectins, which bind glycosylated ligands. This
happens in a dynamic process, forming and breaking bonds
that support capture and rolling under shear stress (50). P- and
E-selectin appear to be the most important selectins expressed
on activated post-capillary venules in non-lymphoid tissues (51).
Rolling leukocytes gets into close contact with endothelial cells,
and this proximity allows inside-out activation of leukocyte
integrins by glycocalyx-presented chemokines. In addition
to producing chemokines themselves, endothelial cells are
also able to capture chemokines produced by stromal cells,
transcytose them, and present them on their luminal surface
(52). This transcytosis of chemokines communicates the nature
of extravascular inflammatory processes to circulating leukocytes
and is mediates by atypical chemokine receptors. A key example
is the Duffy antigen receptor for chemokines that binds both CC
and CXC inflammatory chemokines and is required for optimal
chemokine-induced leukocyte transmigration (52). Cytokines
produced by resident leukocytes also stimulate endothelium
to sequentially upregulate adhesion molecules. These adhesion
molecules bind chemokine-activated leukocyte integrins and
mediate firm adhesion and arrest.
Endothelial Activation May Be Rapid or Sustained
Endothelial responses to inflammatory stimuli can be classified
as type I (in response to e.g., thrombin) or type II (in response
to inflammatory cytokines). Type I responses rely on the release
of pre-synthesised molecules and do not depend on new gene
expression. This very rapid activation allows recruitment of
leukocytes within minutes of the initiating stimulus (53). Type I
responses are typically mediated by G protein-coupled receptors,
whose transient signalling ensures the short-lived nature of the
response (32). G-protein coupled signalling results in elevation
of cytosolic free Ca2+. Free Ca2+ interacts with calmodulin to
drive the phosphorylation of myosin light chain that initiates
the exocytosis of the predominant endothelial storage granule,
the Weibel-Palade body. In addition to the pro-thrombotic
molecule VWF, a subset of Weibel-Palade bodies also contains
angiopoietin 2 (ANGPT2) (54), P-selectin (55), and the powerful
neutrophil chemoattractant CXCL8 (56) that together drive
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vascular destabilisation and rapid leukocyte recruitment. The
rise in intracellular Ca2+ also leads to NO and prostacyclin
production, thus promoting increased blood flow and vascular
leakage. In contrast, type II responses constitute the classical
response to pro-inflammatory cytokines, like interleukin (IL)-
1 and tumour necrosis factor (TNF), resulting in activation
of the inflammatory transcription factors NF-kB and AP1 and
de novo gene expression. Such activation gives rise to a more
sustained and efficient inflammatory response, but with the same
consequences of increased blood flow, vascular leakage, and a
coordinated leukocyte recruitment (Figure 1C). Moreover, both
type I and type II activation of endothelial cells increase vascular
permeability, at least in part by stimulating the formation of
fibrillar adhesions to the extracellular matrix that destabilise
endothelial adherens junctions and allow extravasation of plasma
proteins (57).
Endothelial Signalling Pathways That Regulate
Normal Vascular Function
In addition to signalling induced by inflammatory cytokines, a
number of signalling pathways integrate to regulate endothelial
function, including angiopoietin-1 (ANGPT1)/TIE2- (58),
vascular endothelial growth factor (VEGF)- (59), WNT/β-
catenin-, sphingosine-1-phosphate (S1P)-, and platelet-derived
growth factor (PDGF)-signalling (60). In homeostasis, such
highly interlinked signalling promotes stable endothelial
junctions, as well as interactions with neighbouring mural cells.
Endothelial junctional stability primarily relies on VE-cadherin
homophilic interactions (45, 46). In a resting vessel, VE-cadherin
also directly interacts with VEGFR2, reducing its signalling
potential and protecting the cell from the destabilising effect of
VEGF-A (61). Interestingly, in this setting, VEGF-A mediates
anti-apoptotic signalling through PI3K/AKT-induced eNOS
phosphorylation; exemplifying the complexity of the signalling
involved in endothelial cell maintenance (62). VEGFR2 and
VE-cadherin also merge in a mechano-sensory complex together
with platelet EC adhesion molecule 1 (also known as CD31) that
mediates the endothelial response to shear stress (63). Moreover,
ANGPT1/TIE2-, S1P-, and PDGF-signalling enhance pericyte
recruitment and integrin-mediated adhesion to the extracellular
matrix, further stabilising vessel integrity (64–67). Finally,
endothelial cells also express connexins that form intercellular
gap junctions and contribute to the close communication
between adjacent endothelial cells, pericytes, and vascular
smooth muscle cells (68, 69).
Endothelial Dysfunction Is a Central
Component of Many Viral Syndromes
A common feature of viruses that infect endothelial cells is their
ability to cause severe multi-organ disease. The clinical features
of end-stage viral disease are often similar, with hypoperfusion,
oedema, bleeding, and thrombosis, all indicating breakdown
of central vascular functions (Figure 1D). Typical vascular-
associated histopathological features of different viral infections
are summarised in Table 1. This section reviews common viral
syndromes, with emphasis on their vascular component.
Acute Respiratory Distress Syndrome
In all virus pandemics of the last two decades (Influenza
A H1N1; SARS-CoV, MERS-CoV, and SARS-CoV-2) a high
proportion of affected patients have developed severe illness
and acute respiratory distress syndrome (ARDS) (70–72).
ARDS is a complication to viral pneumonia, characterised by
pulmonary oedema, hypoxaemia, and increasing respiratory
failure, resulting in progressivemulti-organ failure and often fatal
outcomes [exceeding 50% (73)]. Breakdown of the pulmonary
microvascular barrier function is a central feature of ARDS
(74, 75). The histopathological correlates are disruption of
the alveolar epithelial and vascular barriers and accumulation
of protein-rich exudate within the interstitium and alveolus
(76). This eventually leads to diffuse alveolar damage (77, 78),
which is the pathologic hallmark of ARDS. Respiratory viruses
initially infect the upper airway epithelium, but the importance
of this step to alveolar damage is debated. Instead, it might
be that the epithelium merely functions as a portal of entry,
while the alveolar damage primarily results from compromised
vascular integrity (79). The release of potent pro-inflammatory
cytokines and chemokines by resident macrophages, epithelial,
and endothelial cells leads to the recruitment of both innate
and adaptive immune cells (80). These cells cause further
exacerbation of tissue damage. Specific cytokine profiles vary by
the virus, but a general phenomenon for all recent pandemic
viruses is their ability to induce an excessive early cytokine
response (81, 82). Together with immune cell recruitment, this
excessive response strongly correlates with poor outcome. In
H1N1 infection, pulmonary endothelial cells play a central role in
regulating both innate immune cell recruitment as well as innate
cytokine and chemokine production (83). Hence, it is tempting
to speculate if this also holds true for coronavirus-induced
ARDS. A study comparing post mortem-collected tissues from
H1N1 and COVID-19 patients found more severe disruption of
endothelial morphology in COVID-19 patients (3), supporting
this hypothesis. Clinical features of the hantavirus pulmonary
syndrome very much mimic those of influenza- and coronavirus
induced ARDS (11). Nevertheless, it does not appear to be
mediated by release of inflammatory cytokines or morphological
disruption of the endothelium (11, 41). Instead, the dramatic
disruption of vascular barrier function is mediated by direct viral
manipulation of inter-cellular junctions (41, 84), discussed in
more detail in section 4.3.1.
Microvascular Thrombosis and Endotheliitis
Disseminated intravascular coagulation and thrombotic
microvascular occlusion are complications of severe systemic
inflammation and a sequela to most infections discussed
in this article (Table 1). Notably, COVID-19 has been
strongly associated with thrombosis (85), more so than other
coronaviruses and H1N1 (39). This is not entirely surprising,
as severely ill SARS-CoV-2-infected patients have intra-
endothelial viral inclusion bodies, endothelial apoptosis, and
inflammation (endotheliitis) (2–4). The extensive morphological
vascular changes affect a range of organs, from the lung to
the gastrointestinal tract, suggesting widespread endothelial
activation and damage. The true prevalence of microthrombosis
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in COVID-19 is still unknown, as most studies to date do not
include systematic and comprehensive investigation protocols
(39). However, multiple reports have shown cumulative
incidences of thrombotic events around 50% (86), even when
thrombo-profylaxis has been administered. In fact, in one study
56% of patients receiving full anticoagulation were diagnosed
with pulmonary embolism (87). Interestingly, these rates are
similar to those reported in patients with severe sepsis and shock
(39, 88).
Systemic Inflammatory Response Syndrome and
Multi-Organ Failure
As the disruption of vascular functions becomes more
severe, many viral infections culminate in a typical systemic
inflammatory response syndrome, resembling severe sepsis.
In COVID-19, it soon became evident that patients with
severe disease fulfilled all diagnostic criteria for sepsis and
septic shock, even in the absence of bacterial co-infections
(89). This systemic inflammatory response syndrome reflects
overwhelming activation by inflammatory cytokines and other
activators. Initial peripheral vasoconstriction is followed by
uncontrolled vascular dilation, functional hypovolaemia, and
circulatory failure, eventually culminating in multi-organ failure
and death. Nevertheless, cytokine levels in critically ill COVID-
19 patients were lower than in patients with bacterial sepsis (90).
Therefore, it is possible that the severe direct viral damage to
the endothelium (3) further adds to the cytokine-stimulated
breakdown of vascular function in COVID-19. This parallel
between bacterial and viral sepsis is maintained in dengue
vascular permeability syndrome. This syndrome is characterised
by severe hypovolemic shock, in addition to disruption of
haemostasis. Damaged endothelial cells are unable to contain
macromolecules and fluid in the circulation, and there is a
dramatic reduction in blood volume and a corresponding
increase in haematocrit (91). Nevertheless, after a critical period
of 24–36 h, vascular function is restored and a rapid return
to homeostasis ensues (91). This vascular leak appears to rely
mainly on endothelial activation by the viral NS1 protein (92)
via TLR4 (92). Interestingly, TLR4 is also the receptor for LPS, a
bacterial endotoxin and a key driver of sepsis (93).
Kawasaki Disease
While children appear to be relatively resistant to the respiratory
complications of COVID-19, SARS-CoV-2 has been linked
with a recent rise in the occurrence of Kawasaki disease
(94). Kawasaki disease is a rare multi-system inflammatory
response syndrome and vasculitis. It occurs in young children
and is believed to arise due to post-viral immune reactions.
SARS-CoV-2-mediated Kawasaki disease appears to have several
distinct features, including severe haemodynamic instability
and associated myocarditis (95). Localised dermal vasculitis
associated with intra-endothelial SARS-CoV-2 particles has also
been reported in children (4). Interestingly, these children tested
negative for the virus by standard qPCR, but retained SARS-CoV-
2-like particles inside endothelial cells in lesional areas that also
stained positive for SARS-CoV-2 spike protein (4).
ENDOTHELIOTROPISM MAY INFLUENCE
THE OUTCOME OF VIRAL INFECTION
Endotheliotropism
The tropism of a pathogen is the host, cell type or tissue
that supports its growth and, in the context of a virus, the
generation of new progeny. Hence, an endotheliotropic virus
is defined by its ability to attach to, enter, and replicate
in endothelial cells. Such tropism depends on several factors
(summarised in Figure 2) that will be discussed in detail in
section 2.10. For viruses like SARS-CoV-2 (2), henipavirus (9),
hantavirus (11), HPAIV (12), and ISAV (13), examination of
tissues from infected individuals provides strong evidence of
endotheliotropism (Table 1). The observation of intracellular
virus particles by electron microscopy, endothelial expression
of viral proteins by immunostaining, and/or endothelial viral
RNA production by in situ hybridisation shows that endothelial
cells are targeted during infection. Importantly, the specificity of
reagents detecting viral antigens and nucleotides can be ensured
by including tissues from non-infected individuals. Single-cell
RNA-sequencing and analysis of enriched cell populations from
digested tissues can also be used to map the presence of virus
in individual cell types, again with a high specificity. However,
sensitivity is probably a limiting factor of all these techniques,
as cells with a low viral load may evade detection. Furthermore,
neither of the techniques discussed above provide definitive
evidence of generation of infective viral particles, although the
observation of budding viral particles by electron microscopy
is a strong indication. To evaluate whether infective progeny is
produced requires serial passaging of virus, most often in cell
culture. Conversely, the ability to replicate in cultured endothelial
cells does not prove that the virus is endotheliotropic during
natural infection. For example, while both Zikavirus and West
Nile virus readily replicates in cultured endothelial cells (96, 97),
endothelial expression of viral antigens does not appear to be a
prominent feature of human infection.
Challenges Associated With Studying
Endothelial Viral Infections
The discrepancy between observations of replication in cell
culture and the lack of endothelial expression of viral antigens
during natural Zikavirus and West Nile virus infections,
underscores a highly relevant challenge. Often, detailed insight in
themolecular processes of viral infection requires work in cellular
model systems. Because many phenotypic traits of endothelial
cells rely on input from their surroundings, endothelial cells drift
when they are removed from their natural microenvironment
(25). Hence, cultured endothelial cells may show a different
repertoire of surface proteins and other modulators of viral
infection than endothelial cells in tissues, leading to different
outcomes. Moreover, culture systems do not reflect the complex
interplay between stromal and immune cells that makes up the
host defence to infection. Hence, the design and interpretation
of cell culture experiments should always be done with a view to
patient material analyses. However, working with patient samples
also imposes challenges. For highly pathogenic and contagious
agents, the proportion of deceased patients that undergo a full
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FIGURE 2 | Host factors that regulate viral entry into endothelial cells. (A) After replication in mucosal epithelial cells (EPC), viruses can infect endothelial cells (EC)
abluminally or gain access to the luminal surface by transcytosis, paracellular dissemination through activated endothelial junctions, or by being carried by cells that
traffic between blood and tissues, like monocyte/macrophages (Mø). (B) Viruses attach to carbohydrate or protein molecules on the endothelial cell surface. Typically,
attachment to protein receptors and sialic acid variants is highly specific, while attachment to heparan sulphates and scavenger receptors is more promiscuous. (C)
The viral fusion protein is primed, typically by proteolytic cleavage, in the Golgi during biosynthesis, on the cell surface, or in endosomes, depending on protease
susceptibility. (D) Further activation of the viral fusion peptide and viral cytoplasmic delivery may happen on the cell surface or in endosomes and depends on a
conformational change triggered by receptor binding and/or specific pH requirements. Some viruses only fuse with host membranes of specific compositions.
autopsy may be low and could lead to bias. Moreover, analyses of
unfixed tissues must be performed under high-level biosecurity
restrictions, imposing substantially increased costs and limited
availability of specialised equipment. Another challenge is that
endothelial cells reside in tissues. Hence, sampling of material
from human infections commonly originates from the terminal
stage of the disease andmay be poorly suited to study early events
or even the peak viremic phase of infection. However, endothelial
function can be evaluated non-invasively in patients by FMD
(see section 2.3.1), making it possible to study viral effects
on endothelial function at all stages of infection. Experimental
infection of laboratory animals is often used to help our
understanding of infection and disease development, including
the sequential infection of specific cell populations. Because the
pathogenesis of disease often differs between species, animal
models of human viral infections have important limitations.
Hence, the study of animal viruses in their natural hosts may have
an important complementary role in studying host-pathogen
interactions. In conclusion, several approaches should be used
to determine the target cell-type repertoire of a virus. Moreover,
while the use of model systems is essential to obtain information
at high resolution, results should always be interpreted in the
context of observations from natural infections.
The Ability to Infect Endothelial Cells Is
Associated With Virulence
For some viruses, the conversion from a well-tolerated to a
virulent phenotype involves modulations of viral surface proteins
that make the virus able to infect endothelial cells. Well-
studied examples include avian influenza viruses of the H5 and
H7 subtypes and ISAV, all belonging to the orthomyxovirus
family. While low-pathogenic avian influenza virus (LPAIV)
only replicates in mucosal epithelial cells, the conversion of
H5 and H7 strains that defines HPAIV is associated with
a switch in cellular tropism (12, 98). Typically, infection of
susceptible bird species (domestic poultry and black swans) with
HPAIV results in a global vascular infection pattern (12, 99,
100), where immunostaining of viral antigens gives a stronger
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signal in endothelial cells than in epithelial cells of the same
organ (100). Accordingly, HPAIV strains efficiently replicate in
cultured human endothelial cells (101). One should note that
viral replication in endothelial cells does not appear to be a
prominent feature of influenzavirus infection in humans and
other mammals (12, 102). Nevertheless, the introduction of a
miR-126 binding site that specifically prevented viral replication
in endothelial cells, restricted H5N1 replication to the lung in
experimentally infected mice and ameliorated disease in both
mice and ferrets (103). In contrast, preventing viral replication
in haematopoietic cells did not affect disease development (103).
While only coming out of a single study, these findings suggest
that the ability to infect endothelium may play a role in the
extra-pulmonary dissemination and development of generalised
H5N1 infection, also in mammals. Interestingly, single-cell RNA-
sequencing of mouse lung after infection with the pandemic
2009 H1N1 influenzavirus revealed viral mRNA transcription
in 40–50% of endothelial cells (104). Nevertheless, the level
of transcription in individual endothelial cells was low, raising
the question of whether it would be detected by conventional
methods like immunohistochemistry and in situ hybridisation.
Like avian influenza virus, ISAV exists in two variants. Similar
to LPAIV, the ubiquitous non-pathogenic HPR0 variant only
infects epithelial cells at mucosal surfaces and cannot invade
the interior of the fish (105). However, specific modulations
of surface glycoproteins induce a dramatic increase in ISAV
pathogenicity accompanied by a switch in cellular tropism
and multi-organ infection of vascular endothelial cells (13).
Together, these observations suggest that the ability to infect
endothelium may be a critical factor in supporting generalised
viral dissemination and promote disease.
The routes by which viruses reach endothelial cells during
natural infection (Figure 2A) have not been completely mapped.
One interesting question is the extent to which endothelial
cells are infected from the abluminal tissue surface (Figure 2A).
Considering a model where endothelial infection facilitates viral
spread from mucosal sites to the circulation, viral endothelial
entry would be expected to be abluminal. While some virus
receptors, like integrins (106), are abundantly expressed on both
abluminal and luminal endothelial surfaces, both influenzavirus
(107–109) and ISAV (13, 110) attach to cells by binding
sialic acids that are mainly expressed in the glycocalyx on the
luminal surface of endothelial cells (42). Furthermore, work in
polarised endothelial cultures shows that HPAIV infects cells
most efficiently from the luminal side (111). However, to infect
endothelium from the luminal cell surface, the virus must
cross the vascular barrier by other means. These could include
abluminal-luminal endothelial transcytosis or diffusion across
intercellular junctions, perhaps promoted by inflammation or
injury that increases vascular permeability. Moreover, trafficking
cells may carry virus between peripheral tissues and the
circulation [discussed in (112)]. An excellent example of the latter
is Nipah virus that attaches to lymphocytes that do not support
its replication, but act as carriers and promote endothelial
trans-infection (113). Interestingly, budding of H5N1 and ISAV
mainly occurs from the luminal endothelial surface (13, 99, 114),
suggesting that endothelial-produced viral particles, at least for
these viruses, predominantly enter the circulation rather than
being released to surrounding tissues (115).
It should be noted that many viruses cause devastating
pathology at the site of initial infection even in the absence of
spread to distant anatomical sites, exemplified by the extensive
pulmonary damage caused by SARS-CoV-2 and seasonal human
influenza. Hence, endotheliotropism is by no means the only or
even the major determinant of virulence.
The Ability to Cross Specific Vascular Beds
Contributes to Viral Tissue-Tropism
Infection of endothelial cells may also allow circulating
virus particles to enter tissues, provided that the virus can
bud from or be transcytosed to the abluminal endothelial
surface. Again, alternative routes exist to enter tissues from
the blood stream, including diffusion through activated or
compromised endothelium, endothelial transcytosis, or a Trojan-
horse approach relying on infection of cells that traffic between
blood and tissues (112). The relative importance of these
pathways remains unclear.
Arthropod-borne viruses of the flavivirus family, like
Zikavirus and West Nile virus, transmit by mosquito or tick
bites and gain more or less direct access to the circulation.
These viruses provide interesting examples of how circulating
viruses target specific organs and give rise to distinct patterns
of disease. Both viruses primarily cause pathology in the central
nervous system, thus, the ability to cross the blood-brain barrier
is central to pathogenesis. In addition, the ability to cross the
placenta is highly relevant to Zikavirus pathology, where severe
viral damage is restricted to the foetus. In the early phase of
infection, the affinity for endothelial surface receptors appears
to be a key factor in determining these agents’ tissue-tropism
(96, 116, 117). So far, there is limited evidence that Zikavirus
and West Nile virus replicate in endothelial cells during natural
infection. Their ability to cross intact endothelium probably relies
on properties that allow attachment and transcytosis across the
intact endothelial barrier, rather than productive infection (116,
117). Moreover, when the infection progresses, and inflammatory
responses accelerate, increased vascular permeability appears to
promote viral egress further, exemplified by the peripheral TLR3-
dependent inflammation that facilitates West Nile virus entry
into the brain (118). Also, several flaviviruses, including Zikavirus
andWest Nile virus, selectively disrupt the endothelial glycocalyx
of their target tissues via secreted viral proteins, resulting in
increased tissue-specific vascular permeability (119) that may
also facilitate the entry of circulating viral particles.
Could Endothelial Infection Augment Viral
Amplification?
The importance of viral replication in endothelial cells remains
less clear. Nevertheless, the amelioration of disease in mouse
and ferret models of H5N1 influenza upon endothelial-specific
inhibition of viral replication (103) suggests that replication in
endothelial cells at least in some cases promotes a more severe
disease. Considering the abundance of endothelial cells in the
human body, estimated to make up ∼20% of the total number
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of nucleated cells (20), we propose that viral amplification in
endothelial cells deserves further study.
Altogether, there is substantial evidence that the ability
to attach to, infect and/or travel across endothelial cells by
transcytosis contributes to dissemination of viral infection and
disease severity (42).
SPECIFIC FACTORS THAT DETERMINE
THE ABILITY TO INFECT ENDOTHELIAL
CELLS
Viral Attachment to Endothelial Cells
Ranges From High to Low Specificity
The first step of the infectious cycle is the attachment of virus
particles to the host target cell membrane. This process is
mediated by interactions between viral surface glycoproteins
and their corresponding cellular receptors (107, 120, 121). The
endothelial glycocalyx presents a range of molecules involved
in viral attachment and entry (Figure 2B). The binding of
viral glycoproteins to such glycan and protein receptors is
often highly specific and contributes to determining cellular
and host specificity (122), although the presence of a viral
receptor is not sufficient to allow infection. Patterns of virus
binding can be mapped directly by virus binding assays [e.g.,
(13, 123)] or indirectly by mapping the expression of specific
viral receptors by immunostaining. Lately, large datasets from
single-cell RNA-sequencing experiments have been used to map
the expression of receptors and proteins involved in SARS-
CoV-2 attachment and entry by different cellular subsets (124,
125). Nevertheless, information from such analyses must be
considered with the reservation that the correlation between
mRNA and protein expression depends on several factors,
including posttranslational modifications and protein half-life
(125, 126). It should also be kept in mind that even when
expressed at low levels, receptors may still be present in sufficient
amounts to support viral entry. Hence, the expression level of a
viral receptor should be regarded in the context of its binding
affinity for the virus attachment glycoprotein. While low-affinity
binding, as observed between influenzavirus hemagglutinin (HA)
and sialic acids, requires the abundant presence of the receptor
for a high avidity association, a virus that binds its receptor with
high affinity may require much lower expression levels of the
receptor to support robust attachment (120).
Coronaviruses attach to host cells by their surface-exposed
spike (S) glycoprotein that forms the characteristic crown shape
that gave name to this virus family (127). The S protein
consists of two non-covalently attached subunits, the S1 and
S2, responsible for attachment and fusion, respectively (19).
The N-terminal and C-terminal domains of the coronavirus S1-
protein bind carbohydrate and protein receptors, respectively,
and coronaviruses vary widely in their choice of attachment
receptors, including both O-acetylated and non-acetylated sialic
acids and proteins (19, 127). The SARS-CoV-2 S1 protein
predominantly binds the protein ACE2 (35–37), although
binding to 9-O-acetylated sialic acids (128, 129) and CD147
(cluster of differentiation 147) (130) has also been reported.
In addition to strong surface expression in alveolar epithelial
cells and enterocytes of the small intestine, ACE2 is expressed
by arterial and venous endothelial cells and arteriolar smooth
muscle cells (126). When SARS-CoV-2 S1 binds ACE2, the spike
trimer opens up and unshields the S2 core, thus facilitating fusion
protein activation (131).
Henipaviruses (i.e., Nipah and Hendra virus) provide another
example of viral use of a protein receptor for initial cellular
attachment. Henipavirus G proteins specifically bind the vascular
endothelial tyrosine kinase EphrinB2 (120, 132). Nipah virus
also binds EphrinB3, which is expressed to a lesser degree on
endothelial cells, but is highly expressed in the central nervous
system (120). Hantaviral attachment and entry receptors are
associated with more uncertainty, with β3-integrin, gC1qR,
and protocadherin-1 all being proposed as candidates, possibly
with complementary roles (133). Interestingly, attachment to
protocadherin-1 appears to be a clade-specific trait of new
world hantaviruses. The receptor is mainly expressed on airway
endothelial cells, correlating to the pathology mediated by
this clade, which is the causal agent of hantavirus pulmonary
syndrome (133).
Virus binding to sialic acids has been extensively studied
in the context of influenza A. Sialic acids are found on the
outermost end of glycan chains of most cells, but are particularly
abundant in the thick luminal glycocalyx layer covering all
luminal endothelial surfaces (42). Here, they maintain a negative
net charge and promote the vascular barrier function (44). For
influenzavirus, the specificity of binding is regulated by the
nature of the sialic acid linkage to underlying sugars. The ratio
and distribution between 2,3-linked and 2,6-linked sialic acids
in the airways vary greatly between species, and the potential
for airborne transmission within specific host populations is
primarily determined by whether HA preferentially targets 2,3-
linked or 2,6-linked sialic acids (134, 135) [discussed in (108)].
Other viral glycoproteins attach to specific sialic acid derivatives.
For example, ISAV hemagglutinin esterase (HE) exclusively binds
4-O-acetylated sialic acids (110, 136) expressed by endothelial,
some epithelial, and red blood cells of a range of vertebrates (137).
It is important to realise that while successful viral attachment is
a requirement, it may not be sufficient to mediate viral infection.
For example, the LPAIV strains H5N9 and H6N1 match the
HA binding pattern of the endotheliotropic HPAIV H5N1
(123), suggesting that both LPAIV and HPAIV can attach to
endothelial cells. Similarly, non-pathogenic epithelial-restricted
and pathogenic endotheliotropic ISAV HE variants have similar
receptor-binding properties (138).
Virus particles may also attach non-specifically to cells via
interactions with carbohydrates and/or scavenger receptors. Such
attachment strategies are particularly frequent among the flavi-
and filoviruses that typically target a broad range of cells and
appear more promiscuous in their choice of entry receptors.
Subsets of endothelial cells express scavenger receptors that
facilitate the removal of waste macromolecules and apoptotic
cells from blood (24, 139). Stressed virus-infected cells are prone
to exposing the scavenging-signal phosphatidyl serine on their
outer surface, resulting in frequent exposure of phosphatidyl
serine on the outside of the cell-derived viral envelopes (140).
Frontiers in Cardiovascular Medicine | www.frontiersin.org 10 February 2021 | Volume 8 | Article 619690
Fosse et al. Endothelial Cells in Viral Infections
Viral phosphatidylserines facilitate the attachment and uptake
of dengue virus via scavenging receptors, either directly (TIM
family receptors), or indirectly via the natural phosphatidylserine
receptors GAS6 and PROS (TAM family receptor ligands)
(23). Zikavirus appears to have a particularly high affinity for
GAS6, providing a possible explanation for its specific ability
to attach to foetal endothelial cells via the TAM receptor
AXL, cross the placenta, and cause pathology in the foetus
(96). Another example of a non-specific strategy is the initial
attachment of ebolavirus, where uptake is facilitated by scavenger
receptors like TIM-1 (141) and C-type lectins (142), the latter
expressed by hepatic sinusoidal endothelial cells (142, 143). Non-
specific interactions with glycosaminoglycans may also serve as a
primary anchoring step that promotes subsequent engagement
with a specific protein receptor. While not an emerging virus,
endotheliotropic Kaposi’s sarcoma herpes virus (KSHV) is a
good example of this. KSHV attaches to heparan sulphate
glycosaminoglycans before its subsequent specific engagement
of the protein co-receptors EphrinA2 and DC-sign. Together,
this attachment initiates signalling that allows fusion and cellular
entry (144). DC-sign homologues are also thought to mediate the
attachment of other viruses to endothelium, including dengue
(145), Ebola (142), and hepatitis C virus (143).
In conclusion, viral attachment to endothelium occurs
both by highly specific interactions with cellular receptors
and less specific interactions with scavenging receptors or
charged molecules like surface glycosaminoglycans. Binding to
endothelial cell surfaces is required for successful infection and,
as demonstrated by new world hantaviruses, may be linked
to organ-specific pathology. Nevertheless, additional factors are
needed to permit endothelial infection, as demonstrated by
HPAIV and ISAV.
Access to the Endothelial Cytoplasm
Relies on Viral Fusion With the Host Cell
Membrane
In the next step of the infectious cycle, the virus gains access
to the cellular interior. This step is essential for determining
cell tropism. For enveloped viruses, viral entry happens when
the viral envelope fuses with the cell membrane and releases
its contents to the cytoplasm (146). Viral fusion proteins are
activated in a two-step process that results in exposure of a
hydrophobic fusion peptide that can be inserted into the host cell
membrane to start the fusion process. This peptide may consist of
mainly α-helices (class I), mainly β-sheets (class II), or a mixture
of both (class III) (146). Viruses discussed here contain class I or
class II fusion proteins, listed in Table 3.
The Availability of Relevant Proteases Regulates the
Priming of the Viral Fusion Protein
Before fusion can be triggered, class I and class II fusion
proteins must be primed to reach a fusion-competent state,
with the possible exception of hantavirus Gc protein (147).
Priming usually involves a proteolytic cleavage that may take
place in different subcellular compartments or externally.
Accordingly, viral fusion proteins may be primed in the Golgi
during viral biosynthesis, externally at the cell surface, or
in endosomal compartments (Figure 2C), depending on both
intrinsic properties of the fusion peptide and the range of host
proteases present (146). Fusion protein priming plays an essential
role in determining cellular tropism, as many proteases are
expressed in a tissue-specific manner (148). For example, HA
molecules of seasonal influenzavirus are predominantly cleaved
by airway proteases, hence, priming happens on the epithelial cell
surface [discussed in (149)]. This is in contrast to avian H5 and
H7 influenzaviruses, where the conversion to HPAIV involves
the acquisition of multiple basic amino acids at the HA cleavage
site (98). This makes the site susceptible to an extended range
of proteases, including ubiquitous pro-protein convertases like
furin that are encountered in the Golgi apparatus during viral
biosynthesis (150). Thus, susceptibility to pro-protein convertase
cleavage allows the budding of virus particles that express pre-
primed HA molecules and can infect a much wider range of
cells than those depending on priming by tissue-restricted cell
surface proteases.
A pro-protein convertase cleavage site at the S1-S2 position
of the coronavirus S protein also appears to mediate extended
cellular tropism. This cleavage site is present in Mediterranean
respiratory syndrome coronavirus (MERS-CoV), but not in 2003
SARS-CoV. Accordingly, budding MERS-CoV viral particles
express cleaved S proteins, while SARS-CoV viral particles
predominantly express S proteins in the uncleaved immature
conformation (151). Like MERS-CoV, SARS-CoV-2 has acquired
a pro-protein convertase site at the S1-S2 junction that allows
cleavage of the S protein during viral biosynthesis (35, 152,
153) and increases the efficiency of viral fusion with the
plasma membrane (153). Interestingly, protein cleavage by
furin may also expose a C-terminal R/KXXR/K-motif that
strongly promotes cellular internalisation by interaction with
the cellular receptor neuropilin-1 (154). This is also the case
for SARS-CoV-2. Furin-mediated S1-S2 cleavage generates a
SARS-CoV-2 S1 peptide with a C-terminal amino acid sequence
(682RRAR685) that binds neuropilin-1, which acts as a co-factor
to promote viral entry and infection (155, 156). The significance
of furin cleavage to endothelial tropism has not been directly
addressed, but neuropilin-1 is strongly expressed in endothelial
cells in pulmonary tissues (156). Moreover, it is reasonable
to hypothesise that a lesser dependency on surface-expressed
proteases may extend the cellular tropism of SARS-CoV-2 and
could contribute to its ability to infect endothelial cells.
Finally, the henipavirus F protein is an example of a viral
fusion protein that is primed in the endosome, where it is cleaved
by the endosomal protease cathepsin L (157, 158).
The Microenvironment That Triggers Fusion and the
Subcellular Location Where It Is Encountered Vary
Between Viruses
After priming, the triggering of fusion is initiated by a
conformational change that exposes the fusion peptide
(Figure 2D). This conformational change can happen in
response to a single event, often the binding to a specific receptor
or the exposure to low pH. Alternatively, it may require a series
of activating events, like receptor binding followed by exposure
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to low pH and/or proteolytic cleavage. Fusion proteins that
depend on receptor binding only to trigger their activation,
generally fuse with the host cell membrane at the cell surface
(146). The previously mentioned KSHV belongs to this category,
as do most other herpesviruses. This may be relevant when
considering endothelial cell tropism, as some studies suggest
that endothelial endosomes resist fusion of certain viruses, as
discussed below.
A large proportion of enveloped viruses enters the endocytic
pathway before fusion, travelling through endosomal
and lysosomal compartments until they encounter a
microenvironment that provides optimal conditions for
triggering fusion (146). Influenzavirus HA belongs to the
category of fusion proteins triggered by exposure to low pH
alone. Interestingly, human lung microvascular endothelial cells
show less efficient endosomal acidification than human epithelial
cells (159), and this renders endothelial cells less permissive
to infection by seasonal influenzavirus and LPAIV strains. In
addition, endothelial cells express high constitutive levels of
antiviral interferon-induced transmembrane protein (IFITM)
3 in endosomal and lysosomal compartments. This protein
arrests endosomal fusion of seasonal human influenzavirus in
endothelial cells at the hemifusion stage (160). Overcoming these
obstacles, HPAIV strains have a less stable conformation of the
HA molecule that allows fusion to take place at a higher pH
(159) and allows infection in early endosomal compartments.
The ability to efficiently fuse at a higher pH probably also
mediates the relative resistance of HPAIV to the antiviral
action of IFITM3 (161). Notably, it is unknown whether the
inefficient endosomal acidification and high expression of
IFITM3 are specific to the lung microvasculature or a general
feature of endothelial cells. The relevance of these findings to
other anatomical sites is therefore unclear. Furthermore, the
efficiency with which IFITM proteins inhibit viral entry vary
between viruses. Flaviviruses, represented by dengue and West
Nile virus, show a similar susceptibility to IFITM proteins as
influenza H1N1, while arenaviruses appear to overcome their
action (162).
In viruses where separate viral glycoproteins mediate cellular
binding and fusion, interactions between these proteins may
also regulate viral entry. This has been extensively studied
in paramyxoviruses, where three different models have been
proposed: First, the provocateur model, where viral binding
to cellular receptors, often sialic acids, triggers an activating
interaction between the viral attachment and fusion proteins;
Second, the clamp model, where the interaction between the
viral attachment and fusion proteins inhibits the fusion protein;
And third, the safety-catch model, where the fusion protein
head tightly assembles with the stalk protein of the attachment
viral glycoprotein in the endoplasmic reticulum during viral
bio-synthesis, but is released at the target cell membrane upon
receptor binding (163). A highly relevant example of the safety-
catch model is the binding of endotheliotropic henipaviruses,
where binding of the globular head of dimeric G-proteins to
their cellular receptors (EphrinB2 and B3) mediates a distant
structural change that releases the association with the F-protein,
thus allowing fusion to be triggered (163).
The ISAV fusion process is still incompletely characterised,
but appears to have features in common with both influenza-
and paramyxoviruses. For the F protein to reach its fusion-
competent trimeric state, both low pH and proteolytic cleavage
is required (164). The conversion to virulence that includes a
gain of endotheliotropism, always involves deletion of a variable
number of amino acids in a highly polymorphic region [HPR,
including amino acids 320–374 (165)] at the base of the stalk
of the hemagglutinin esterase molecule (166, 167). In apparent
homology to the destabilisation of influenza HA that is associated
with the conversion of LPAIV to HPAIV, the shortening of the
stalk that results from HPR-deletion destabilises the interaction
with the fusion protein. This destabilisation appears to facilitate
the dissociation of HE and F proteins upon receptor binding
and allow activation of viral fusion at neutral pH (166, 168).
In contrast, no increase in fusion efficiency was observed
when comparing pathogenic and non-pathogenic variants of
the HE and F proteins in the presence the exogenous protease
trypsin and low pH (168), perhaps mimicking the situation at
mucosal surfaces.
Exposure of the fusion peptide by receptor binding followed
by protease cleavage, sometimes with the added requirement
for low pH, has been studied extensively in coronaviruses
and is therefore of great relevance to the current pandemic.
Endothelial cells express a wide range of proteases on their
luminal surface that take part in activation of surface receptors
with homeostatic functions. As discussed above, the SARS-
CoV-2 S protein is cleaved during biosynthesis by pro-protein
convertases. However, further S-protein processing occurs at
the target cell surface by the protease TMPRSS2 and in target
cell lysosomes by cathepsin, and the three proteases appear to
have cumulative effects in regulating the entry of SARS-CoV-2
(153). In contrast to cathepsins that are ubiquitously expressed
in lysosomes, TMPRSS2 expression differs between tissues and
has been proposed to restrict the target cell population of SARS-
CoV-2 (169). While TMPRSS2 is strongly expressed by human
endothelial cells in culture (124), only a minor fraction of tissue
endothelial cells appears to express the TMPRSS2 gene under
basal conditions (125, 170, 171), perhaps limiting endothelial
SARS-CoV-2 infection. Yet, endothelial cells are infected (2,
3), presumably assisted by the additive action of pro-protein
convertases and cathepsins.
The composition of the host cell membrane may also
regulate the potential for viral fusion. A prime example is
the Andes hantavirus that shows a strict requirement for
membrane cholesterol that is shared by several other pathogenic
hantaviruses (172). Similarly, dengue virus requires anionic lipids
in the host cell membrane and therefore fuse in later endosomal
compartments than their pH-requirements would indicate (173).
Replication in Endothelial Cells Requires
Evasion of Intrinsic Antiviral Responses
Once inside the cell, efficient viral replication depends on
adaptation to the host cell machinery. The ability of viral
polymerase complexes to function efficiently in the cellular
interior is a key factor for determining species tropism and
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virulence, as demonstrated for PB2 and PA subunits of influenza
(174, 175). Moreover, viral polymerase subunits must be able
to associate with the proteins that mediate nuclear import in
the cell type in question (176). Nevertheless, successful viral
adaptation to the endothelial cell type may rely even more
on the ability to evade intracellular antiviral responses that
vary between cell types. For example, replication of pathogenic
hantavirus was sustained in cultured endothelial cells for up
to 48 h, while infection with a non-pathogenic strain resulted
in rapid upregulation of antiviral proteins that prevented
efficient generation of infective progeny (177). This correlates
to observations in ISAV infection, where a pathogenic isolate
of low virulence infected endothelial cells early in the course
of infection, but was rapidly eliminated, while a high-virulent
pathogenic isolate that caused a less pronounced antiviral
response, maintained replication in endothelial cells over a
prolonged period of time (178, 179). In conclusion, the efficiency
of viral replication in any cell type relies on successful viral
adaptation to the cellular replication machinery as well as the
ability to evade intrinsic antiviral responses.
THE ENDOTHELIAL CELL RESPONSE TO
VIRAL INFECTION
Cellular Detection of Viral Components
Activates NF-kB and Type I Interferon
Signalling
All cells are capable of intrinsic antiviral responses. First, cellular
pattern recognition receptors at different subcellular sites detect
the presence of viral nucleic acids. The Toll-like receptors
TLR7 and TLR8 (both detecting RNA), and TLR9 (detecting
DNA) bind viral nucleotides on cell surfaces or in endosomes.
Once released to the cell interior, viral contents can also be
detected by the cytoplasmic receptors RIG-like (e.g., retinoic
acid-inducible gene-I, RIG-I, detecting single stranded RNA),
melanoma differentiation-associated protein 5 (MDA5, detecting
double stranded RNA), and cyclic GMP-AMP synthase (cGAS,
detecting DNA). Recent work suggests that the surface-expressed
receptor TLR4 can also be activated by secreted viral proteins
(92, 180). Stimulation of these receptors initiates signalling that
results in the intracellular activation of inflammatory (NF-kB)
and type I interferon (interferon response factors 3 and 7)
transcription factors (181). Similar to other cell types, endothelial
cells mount type I interferon responses upon viral infection
(177, 182). This response stimulates the transcription of a
range of interferon-stimulated genes (ISG) that inhibit viral
infection (183). Furthermore, endothelial activation of NF-kB
results in upregulation of a range of molecules that mediate
leukocyte adhesion and shift the endothelial surface toward a
pro-thrombotic stage (184) (Figure 1C).
Inflammatory and Antiviral Signalling Is
Also Activated in Non-infected Cells
Non-infected cells, including endothelial cells, also respond to
viral infection (104). Endothelial cells express receptors for
type I and II interferons, as well as a range of cytokines and
chemokines upregulated in and secreted from virus-infected
cells or activated immune cells (Figure 1C). Such activation is
highly prevalent in patients with H1N1 2009 pandemic influenza
and COVID-19 (81, 90). Another example of such humoral
activation is the vasoactive proteins secreted by dendritic cells
and macrophages in ebolavirus infection (180). In addition, non-
infected cells can be activated in viral infection by diffusion
of second messengers across intercellular gap junctions (185).
Although only demonstrated for the cGAS second messenger
cGAMP(2’,5’), it is likely that other low molecular weight
(<1,000 Dalton) second messengers also share this route (186).
Gap junction-mediated activation of endothelial cells has not
been explored in the context of viral infection. However, the
mechanisms could be highly relevant, as endothelial cells form
gap junctions with other endothelial cells, vascular smooth
muscle cells, and pericytes that contribute to the maintenance of
vascular homeostasis (68, 69).
Endothelial Cells Are Effectors of the Host
Response to Viral Infection
Endothelial NF-kB activation is capable of mediating all cardinal
signs of inflammation. Redness, swelling, heat, and pain result
from an increase in local blood flow, leakage of protein-
rich plasma, and the recruitment of leukocytes that release
mediators working on C-type sensory nerve fibres. Invading
leukocytes attempt to eliminate the initiating stimulus by
killing infected cells and removing cellular debris. However, the
powerful inflammatory mediators released by leukocytes also
exacerbate vascular activation, cause tissue damage, and loss
of function (Figures 1C,D). The first cells recruited to sites
of inflammation are neutrophils that infiltrate tissues within
minutes after endothelial type I activation (53). Nevertheless,
a recent study showed that recruitment of non-conventional
CD8 αβ-T cells from the microvasculature occurred with similar
ultra-rapid dynamics when a rhabdovirus was inoculated in the
nasal cavity of trout, and that this recruitment was central to
controlling infection (187). The mechanisms involved are not
yet fully understood, but appear to depend on viral activation
of tyrosine kinase receptors (187). Altogether, the dynamic
vascular expression of adhesion molecules and chemokines in
inflammation contributes to tight coordination of the leukocyte
recruitment process. Such control is particularly relevant in viral
infection, where pathology often arises from the host response
to infection, rather than the action of the virus itself. The
importance of controlling early innate responses and preventing
their spiralling out of control is clearly demonstrated in COVID-
19, where an increased neutrophil-lymphocyte ratio is a feature
of severe disease and has emerged as a prognostic indicator of
outcome (188).
Endothelial Cells Modulate Immune Cell
Activation in Viral Infection
Infection with some endotheliotropic viruses, like SARS-
CoV-2 (2) and Nipah (9, 189), is associated with extensive
endothelial damage and endotheliitis (Table 1). In contrast,
other endotheliotropic infections are characterised by a lack of
perivascular cellular infiltrates and/or endothelial cytopathology
(11, 13). This suggests suppression of cytotoxic T cell
responses, which would otherwise attempt to limit infection
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by killing infected cells. In this context, it is interesting to
consider the immunomodulatory potential of antigen-presenting
endothelial cells. As part of protective measures against self-
reactive T cell responses, interferon-induced MHC class II
allows endothelial cells to act as semi-professional antigen-
presenting cells (190). Importantly, type I interferon signalling
also upregulates programmed cell death 1 (PD-1) ligand (PD-
L1) in endothelial cells (191), and T cell activation by PD-
L1-bearing lymphatic endothelium induces accumulation of
PD-1 and T cell deletion (192). Hence, endothelial viral
antigen presentation is likely to promote immune tolerance
to protect vascular integrity, but also provide a niche for
viral evasion of immune responses (41). Interestingly, PD-L1
on both haematopoietic and non-haematopoietic cells reduced
viral clearance in experimental LMCV infection, yet improved
survival by reducing immunopathology (193). There has been a
recent discussion about the possible impact of PD-1 blockade,
a commonly used cancer immunotherapeutic, on SARS-CoV-2
infection. Nevertheless, current clinical data suggest that it does
not change the outcome in COVID-19 (194).
MOLECULAR MECHANISMS THAT
DISRUPT VASCULAR FUNCTION IN VIRAL
INFECTION
Maintaining a Stable Vasculature Is Key to
Preventing Viral Pathology
Studies of the S1P-receptor illustrate the central role endothelial
cells have in maintaining the vascular barrier and preventing
detrimental inflammation. Activation of endothelial S1P-
signalling by a synthetic agonist suppressed early innate
immune responses and improved survival in mice infected with
H1N1 2009 pandemic influenzavirus (83). S1P-administration
also ameliorated hantavirus-induced endothelial hyper-
responsiveness in a cell-based permeability assay (195), showing
that S1P-signalling has a generalised stabilising effect on the
vasculature. Underscoring the importance of endothelial
signalling in maintaining a functional vasculature, mice with
endothelial-specific deletion of the glucocorticoid receptor
showed increased mortality in systemic inflammatory response
syndrome, with exaggerated vascular instability and pro-
inflammatory signalling (196). This makes it tempting to
speculate if some of the positive effects of glucocorticoid-
treatment in severe COVID-19 (197) could be mediated by
vascular stabilisation. An overview of the molecular mechanisms
that regulate the stability of vascular junctions in viral disease is
provided in Figure 3.
Disruption of Vascular Function by Host
Defence Mechanisms
Excessive NF-kB and Type I Interferon Signalling
Disrupts Endothelial Function
Signalling that confers powerful antiviral actions also has
less beneficial effects (Figure 1). Type I interferon responses
are associated with endothelial dysfunction in systemic lupus
erythematosus (198). They also accelerate the development of
atherosclerosis in both mice and humans, at least in part by
reducing NO bioavailability [reviewed in (199)]. Finally, type
I interferon skews the profile of endothelial-secreted molecules
toward a pro-thrombotic state and inhibit normal angiogenic
functions that may be relevant to reparatory processes (200).
Many ISGs have dual, counteractive functions, a highly relevant
example being PAI-I (201). PAI-I is an extracellular serine
protease inhibitor that counteracts viral entry by inhibiting
tryptase, trypsin, and TMPRSS2, thereby inhibiting priming of
influenzavirus HA (201). However, PAI-I is best known for
its pro-thrombotic actions and is a biomarker for endothelial
dysfunction (202). Hence, excessive or prolonged endothelial
secretion of PAI-I will disturb the delicate maintenance of blood
fluidity (Figure 1D).
Similarly, excessive endothelial NF-kB-activation is linked to
the disruption of normal vascular function. Stimulation of NF-kB
promotes a pro-inflammatory and pro-thrombotic endothelial
phenotype (184) and inhibits NO production (203). Accordingly,
endothelial-specific deletion or inhibition of NF-kB protects
mice from developing atherosclerosis (204) and abrogates the
derangement of vascular functions in experimental sepsis (203).
In conclusion, prolonged or excessive endothelial activation in
viral disease is likely to result in vascular dysfunction that affects
both infected and bystander endothelial cells.
Mast Cell Activation Induces Vascular
Hyper-Permeability
Host cells may also secrete other vasoactive molecules. One
of many examples is the vascular hyper-permeability induced
by vessel-associated mast cells in dengue-infection, involving
tryptase-mediated breakdown of intercellular endothelial
junctions (205). Tryptase levels correlated with the severity of
symptoms in two patient cohorts (205), supporting that this
mechanism is relevant to disease pathogenesis.
Disruption of Vascular Function by Viral
Components
Viral Surface Proteins That Dysregulate Vascular
Homeostasis
Many of the cellular molecules that viruses bind (Table 2) are
also central to the regulation of vascular function (209). Hence,
viral infection has potential to dysregulate their signalling. In
the COVID-19 pandemic, the dual roles of ACE2 have been
subject to much attention (19, 210), on one hand serving as
a key factor for viral attachment and entry (153), and on the
other hand, counteracting the detrimental cardiovascular effects
of ANG-II (19, 38), highly relevant to disease. Interestingly,
internalisation of the closely related SARS-CoV is accompanied
by internalisation and shedding of ACE2 (211, 212). By
homology, it is broadly assumed that the same is true for SARS-
CoV-2 (19, 210, 213). The resulting loss of the ACE2 catalytic
effect at the cell membrane may be a significant contributor to
pathology in COVID-19 (211, 213). Briefly, such downregulation
of ACE2 favours the progression of inflammatory and thrombotic
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FIGURE 3 | Functional regulation of vascular permeability in viral disease. The vascular barrier integrity is controlled by two main components: the glycocalyx (GC) and
the endothelial adherens junctions (EAJs). (A) In the resting state, several signalling pathways promote VE-cadherin-supported junctional integrity. In addition to
maintaining an intact vascular barrier, VE-cadherin-signalling also skews VEGFR2-signalling toward eNOS-activation and survival-promoting pathways. (B) Upon type I
(thrombin) and/or type II (IL-1, TNF) activation, the cytoskeleton is reorganised, and fibrillar adhesions are formed in an ANGPT2-dependent manner. Furthermore,
activation by cytokines or flaviviral NS1 stimulates endothelial production of enzymes that mediate glycocalyx-shedding and further disrupts the vascular barrier.
Hantavirus surface proteins bind and inactivate the EAJ-supportive action of β3-integrins, thereby increasing VEGF-stimulated permeability. In addition, hantavirus N
protein promotes RhoA-signalling and increases permeability independent of VEGF-signalling.
TABLE 2 | Viral attachment molecules that bind endothelial surface molecules.
Virus Viral attachment protein Endothelial receptor References
SARS-CoV-2 S protein, subunit S1 Angiotensin converting enzyme (ACE)-2 (35–37)
Nipah and Hendra henipavirus G protein EphrinB2 (B3) (120, 132)
New world hantavirus Gn protein β3-integrin (133)
protocadherin-1
Influenza A, H5N1, H7N1 (HPAIV) HA, subunit H1 α-2-3-linked N-acetyl-sialic acid (134, 135)
Infectious salmon anaemia virus (HPR-deleted) HE 4-O-acetylated N-acetyl-sialic acid (110, 206)
processes, triggered by enhanced and unopposed effects of ANG-
II (19, 38, 213).
Another highly interesting SARS-CoV-2 interaction partner is
the VEGFA- and semaphorin-binding b1 pocket of neuropilin-1
(155, 156). To our knowledge, the effects of this interaction on
vascular permeability has not yet been evaluated in the context
of SARS-CoV-2. Nevertheless, binding of C-end R/KAAR/K-
peptides to this pocket generally increases vascular permeability
in a VEGFR2-independent manner (214), and, upon injection,
such peptides induce vascular leakage and are retained in
tissues (154).
Another example of viral interactions with the VEGFR2-
signalling pathway is the dysregulation of integrins in hantavirus
pulmonary syndrome (Figure 3). Integrins have central functions
in maintaining vascular barrier functions (215, 216), and
β3-integrins specifically regulate VEGFR2-dependent vascular
permeability (217). Pathogenic hantaviruses bind αvβ3 integrin
in the bent, inactive conformation (218). The resulting reduction
in αvβ3 integrin signalling results in VE-cadherin internalisation
and increased vascular responsiveness to VEGF-A (195),
mimicking the actions of αvβ3 integrin antagonism or genetic
silencing of β3 integrin (57, 219) (Figure 3B).
EphrinB2, the cellular interaction partner for the henipavirus
G protein (132), also modulates VEGFR2-signalling (220–
222). Ephrins and Ephs are membrane-bound tyrosine kinases
that signal bidirectionally. This leads to forward (in the
Eph-bearing cell) and reverse (in the Ephrin-bearing cell)
signalling in adjacent endothelial cells (223). EphrinB2-Eph4
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TABLE 3 | Viral fusion proteins and factors that regulate their activation.
Virus Protein containing
fusion peptide
Priming proteolytic cleavage (site) Triggering References
SARS-CoV-2 S protein (S2 subunit) Cleavage of S1 and S2 subunits that
remain non-covalently bound (surface or
endosome)
Proteolytic cleavage at the S2’ site,
immediately upstream of the fusion
peptide
(35)
Nipah and Hendra henipavirus F protein Cleavage of F0 by cathepsin into F1 and
F2 (endosome)
G protein receptor binding that mediates
dissociation of the F protein
(157, 158,
163, 207)
New world hantavirus Gc protein Incompletely understood Low pH, membrane cholesterol
composition
(172)
Influenza A, H5N1, H7N1
(HPAIV)
HA, subunit H1 HA0 cleaved to HA1 (receptor binding)
and HA2 (fusion), subunits remain





F protein Cleavage of F0 by unknown protease into
F1 and F2 (location not known)
Low pH, not fully characterised (164, 208)
signalling appears to support endothelial-pericyte interactions
after cerebral ischaemic injury and promote the return to a
functional vasculature (224). While EphrinB2-Eph4 signalling
is dispensable for blood-endothelial barrier function, it is a
critical stabiliser of lymphatic endothelial junction integrity
(225). Therefore, it is tempting to speculate if viral EphrinB2
binding and internalisation could modulate EphrinB2-Eph4
signalling in henipavirus-infected endothelial cells. However,
to our knowledge this has not been experimentally tested.
The surface proteins of henipaviruses also mediate another
central vasculopathy, namely the endothelial syncytia formation
observed in both human (9) and hamster (189), a species
commonly used to study the disease. This is reflected in cultured
cells, where co-expression of henipavirus G and F proteins
induces cellular fusion within 12 h (226).
Viral attachment to sialic acids also has the potential to affect
vascular functions. In several viral infections, including influenza,
a reduction in virus particle binding to host tissues is observed
as the infection progresses (227), limiting superinfection (228).
The mechanism behind the loss of virus binding is not
fully characterised, but several studies suggest that sialic acid
cleavage by viral neuraminidase may be involved (228–230).
This is interesting, as sialic acids in the endothelial glycocalyx
contribute to maintaining vascular integrity, and their removal
has been associated with increased microvascular permeability
(44). However, the consequences of virus-mediated sialic acid
modulations on vascular function remain largely unknown.
Secreted Viral Proteins Damage Vascular Endothelial
Cells Independent of Their Infection Status
Another virus family that targets the endothelial glycocalyx
is the flavivirus family. An extensively studied example is
the dengue virus-mediated vascular barrier breakdown that
involves disruption of glycocalyx integrity in cell culture and
animal models (231, 232). The damage is mediated by the
secreted non-structural viral protein NS1. Dengue NS1 directly
induces shedding of the pulmonary endothelial glycocalyx
by upregulation of endothelial sialidases, cathepsin L, and
heparanases (232) (Figure 3B). In fact, NS1 proteins of different
flavivirus strains selectively target the endothelium of specific
vascular beds in a pattern that corresponds to virus tropism
and causes disruption of the endothelial glycocalyx and severe
vascular leakage (119). At least for dengue virus, the capillary
leak induced by NS1 is reduced by inhibition of TLR4 (92),
suggesting that this receptor mediates the response to NS1.
Interestingly, soluble viral glycoproteins appears to counteract
the disruption of the vascular barrier caused by particle-bound
viral glycoproteins in Ebola virus infection (233). Notably,
infection of endothelial cells mostly occurs after clinical signs
have developed in natural Ebola infection (16). Hence, most
vascular damage is probably indirect, for example by the
action of vasoactive cytokines secreted by dendritic cells and
macrophages (180).
Modulation of Endothelial Signalling by Other Viral
Proteins
The Andes hantavirus nucleocapsid (N) protein mediates an
additional aspect of the increased microvascular permeability
observed in hantavirus pulmonary syndrome (84). In contrast
to disrupted integrin signalling that targets VEGF-stimulated
vascular permeability (195), the N protein increases endothelial
cell size by interfering with tuberous sclerosis complex inhibition
of mTOR signalling (84). Because tuberous sclerosis complexes
also regulate RhoA-signalling, the inhibition also activates RhoA
and increases basal (unstimulated) vascular permeability (84)
(Figure 3B).
In conclusion, both structural and non-structural viral
proteins modulate and disrupt endothelial function at different
stages of the infectious cycle. Importantly, cellular damage can be
induced by secreted viral proteins, hence, uninfected endothelial
cells can also be affected.
CONCLUDING REMARKS
We have reviewed endothelial cell-virus interactions in emerging
viral infections. We aimed to illustrate the diversity of such
responses and identify common features that will bring us closer
to understanding the role of endothelial cells in viral disease. This
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is important. First, because many pathogens that pose a threat
to global human and animal health infect endothelium; second,
because conditions characterised by endothelial dysfunction is
associated with severe outcomes of infection with SARS-CoV-
2; and third, because dysregulation of vascular function confers
disease in many life-threatening viral infections.
All possible viral entry ports are in close contact with
endothelial cells, and the diversity of endothelial phenotypes
probably contributes to guiding viral infection and pathology.
In addition, the switch from a non-pathogenic to a virulent
phenotype that causes disseminated infection and generalised
disease is associated with a gain in endotheliotropism, at least
for some viruses. This endothelial tropism is determined by both
virus and host factors that regulate virus attachment, fusion,
and replication. The viral attachment has a prominent role in
species- and tissue-tropism but is not sufficient for infection
to occur. Rather, the viral fusion process appears to be a
strong determinant of cellular tropism. Some essential features of
endothelial cells that regulate such viral fusion include inefficient
endosomal acidification and high levels of antiviral proteins
in endosomal compartments (159, 161). Hence, an increased
ability to fuse on the cellular surface or in early endosomal
compartments may facilitate, but is not absolutely required, for
endothelial infection. This may for example be achieved by
conformational destabilisation of the fusion protein that makes
it more susceptible to activation (159, 168). Much of the work
that has identified specific factors regulating endothelial tropism
comes from the study of orthomyxoviruses. Hence, efforts
should be made to understand if these factors also determine
endotheliotropism in other viruses. Studies of viral fusion are
challenging in other settings than cell culture, but should be
interpreted with a view to natural infections.
A systemic inflammatory response syndrome with the
breakdown of vascular function characterises severe viral disease,
and it has clear parallels to bacterial septic shock (89). There
is a loss of control of vascular permeability, ranging from
local oedema to severe hypovolemic shock, and a microvascular
thrombosis that may proceed to consumptive coagulopathy.
Despite the similarity of clinical signs observed in infection
by different endotheliotropic viruses, the underlying disease
mechanisms differ. For example, the extent of direct endothelial
damage and endotheliitis vary widely, from extensive in
henipavirus and SARS-CoV-2 infection (2, 3, 9) to minimal in
hantavirus (11, 41) and ISAV (13) infection. Nevertheless, all
these agents cause severe vascular compromise, oedema, and
bleeding. This has two implications. First, mechanisms other than
direct endothelial damagemay cause vascular dysfunction in viral
disease. Second, the immunomodulatory role of endothelium
probably limits T cell killing of infected endothelial cells in some
viral infections, possibly providing a niche for viral replication
(192). Activation of inflammatory and antiviral pathways in
endothelial cells orchestrate leukocyte recruitment to sites of
infection and generate ISGs that potently inhibit viral replication.
However, the same pathways also disrupt vascular function
(33, 204, 234) by inducing a pro-inflammatory, pro-thrombotic
vascular profile. In addition, direct interactions between viral
proteins and endothelial components that regulate the vascular
barrier contributes to the vascular leakage seen in viral disease
(84, 92, 119, 195, 227, 228).
The biosecurity risks associated with many emerging viruses
together with the invasiveness of sampling required for obtaining
endothelial cells from patients, limit studies of viruses during
natural human infection. However, all available model systems
have significant limitations. To this end, we propose that
experiments in cell and laboratory animal models, studies
of animal pathogens in their natural hosts, and analysis
of patient materials must be combined to fully understand
viral interactions with the endothelium during infection
and disease.
We hope that this article is a step toward a more generalised
understanding of how endothelial cells are targeted in viral
disease, either by direct infection or as bystanders. Such
knowledge is likely to improve strategies for managing patients
with viral infection. This is particularly important in crises like
the current pandemic, where resources are exhausted by the high
prevalence of infection. A better understanding of underlying
mechanisms could help us evaluate the rationale of suggested
strategies. One example is the stratification of risk in patients
by FMD in COVID-19 (7), another the use of pleiomorphic
therapies, including statins, glucocorticoids, and ACE-inhibitors,
to stabilise vascular function in a non-specific manner in severe
viral infection (235, 236).
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